Final answer:
Secukinumab and Ixekizumab are the two IL-17 inhibitors approved for pediatric patients with plaque psoriasis, providing effective treatment options for this inflammatory skin condition.
Step-by-step explanation:
The two IL-17 inhibitors indicated for pediatric patients with plaque psoriasis are Secukinumab and Ixekizumab. These drugs function by targeting and inhibiting the activity of interleukin 17 (IL-17), a cytokine that plays a crucial role in the inflammation process associated with psoriasis. By blocking IL-17, these medications help to reduce the inflammation, redness, and scaling that characterize plaque psoriasis, offering relief to patients. Both Secukinumab and Ixekizumab have been studied and found to be effective in this patient group, providing additional treatment options for young patients suffering from this condition.